GE HealthCare enters its third-quarter report with two very different stories running side by side. Last quarter, organic orders jumped 11.1%, the fastest pace since the company left General Electric, pushing backlog to a record $23.9 billion and book-to-bill to a record 1.15. At the same time, the Patient Care Solutions segment shrank 13.5% organically, posted negative segment profit and was placed under formal strategic review. The question for the October 28 release, due before the market opens, is whether the strong order book can start showing up in revenue and margins while PCS stops getting worse.
The Street is looking for adjusted earnings of $1.21 per share on revenue of about $5.36 billion. That would be roughly 13% earnings growth on only about 4% sales growth, so the quarter depends far more on margin execution than on the top line. The whisper number of $1.25 sits modestly above consensus, a sign that some investors expect another beat. Management reaffirmed its full-year earnings outlook of $4.80 to $5.00 per share. Consensus of $4.89 sits near the middle of that range. Notably, the company held that range even after picking up a $0.04 tariff refund and a lower tax rate, which suggests caution built into the plan rather than a stretched target.
Margins are the main test. Adjusted EBIT margin was 14.2% last quarter, down 40 basis points from a year earlier, even though the business excluding PCS expanded about 100 basis points. Inflation in memory chips, oil and freight cost roughly 120 basis points. The full-year margin target of 15.4% to 15.7% was already lowered in the first quarter, and hitting it requires a meaningful second-half step-up. A third-quarter margin that moves clearly toward that range, helped by the price and cost actions management said were beginning to work, would support the guidance. A flat year-over-year margin would push more of the burden into the fourth quarter.
On PCS, a smaller decline and a return toward breakeven would show that the fulfillment and supply-chain problems were fixable operating issues rather than a sign of lasting weakness. Any detail on the strategic review, whether that points toward keeping, selling or restructuring the unit, could matter as much as the reported numbers. Pharmaceutical Diagnostics is the other bright spot to track. It accelerated to 14.6% organic growth, and Flyrcado doses reached 545 per week in late July, roughly double the level of two quarters earlier. Continued progress would add credibility to the target of more than $500 million in Flyrcado sales by 2028.
Orders deserve careful reading. Some easing from 11% growth would be reasonable, since large enterprise contracts such as the roughly $500 million Catholic Health agreement and the University Hospital Essen win can make results lumpy. Book-to-bill holding above 1.0 and backlog staying near record levels would confirm that demand is broad rather than a single strong quarter. Progress on the European approval for photon-counting CT and on recurring software such as True Definition DL would add to the product-cycle case. The departing CFO and interim finance chief add some uncertainty about how the outlook is presented.
Sentiment has turned from 27.2% bearish to 10.2% bullish, yet the shares have gained only 0.6% since the last report, trailing the S&P 500 by three points. At $69.76, the stock sits just below its 200-day moving average and near the middle of its post-earnings range of $63 to $75.65. Expectations look somewhat better but not stretched. The report most needs to show that the record backlog is beginning to turn into revenue with better margins, and that PCS has stopped deteriorating. If both happen, the company's improving narrative holds up. If margins stall or PCS slides further, the strong order book alone may not be enough to support the stock.